Provided by Tiger Fintech (Singapore) Pte. Ltd.

resTORbio, Inc.

2.28
0.0000
Volume:- -
Turnover:- -
Market Cap:11.87M
PE:-1.16
High:2.28
Open:2.28
Low:2.28
Close:2.28
52wk High:69.44
52wk Low:2.28
Shares:5.21M
Float Shares:3.69M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9700
EPS(LYR):-16.8824
ROE:-66.75%
ROA:-38.47%
PB:0.17
PE(LYR):-0.14

Loading ...

Company Profile

Company Name:
resTORbio, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
resTORbio, Inc., a clinical-stage biopharmaceutical company, develops medicine to treat aging-related diseases. Its lead program is selectively inhibits the target of rapamycin complex 1 (TORC1), an evolutionary conserved pathway that contributes to the age-related decline in function of various organ systems, including immune, neurologic, and cardiac functions. The company's lead drug candidate is RTB101, an oral, selective, and potent inhibitor of TORC1 that is in Phase 1b/2a clinical trial for the treatment of Parkinson's disease, as well as to treat neurodegenerative diseases. resTORbio, Inc. has collaboration with TrialSpark to investigate RTB-101 for COVID-19 on the Project Covalence platform. resTORbio, Inc. was founded in 2016 and is headquartered in Boston, Massachusetts.